share_log

Femasys | 10-Q: Q2 2024 Earnings Report

Femasys | 10-Q: Q2 2024 Earnings Report

Femasys | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/08 20:49

Moomoo AI 已提取核心信息

Femasys Inc. reported Q2 2024 financial results with revenue declining 30.9% to $221,484 from $320,514 in Q2 2023, primarily due to timing of international sales. Cost of sales decreased 33.8% to $73,125, reflecting reduced sales and manufacturing efficiencies. The company's net loss widened to $4.7 million from $2.9 million year-over-year.Research and development expenses increased 29.4% to $2.0 million, driven by higher material, development and clinical costs. Sales and marketing expenses rose significantly to $975,190 from $128,899 as the company built its commercial team for FemaSeed launch. General and administrative expenses grew 18.8% to $1.6 million due to increased facility and compensation costs.As of June 30, 2024, Femasys had cash and cash equivalents of $13.5 million, which management expects will fund operations into July 2025. However, the company noted substantial doubt about its ability to continue as a going concern beyond 12 months without additional financing. The company is advancing commercialization of its FDA-cleared FemaSeed infertility solution and conducting pivotal trials for its FemBloc permanent birth control candidate.
Femasys Inc. reported Q2 2024 financial results with revenue declining 30.9% to $221,484 from $320,514 in Q2 2023, primarily due to timing of international sales. Cost of sales decreased 33.8% to $73,125, reflecting reduced sales and manufacturing efficiencies. The company's net loss widened to $4.7 million from $2.9 million year-over-year.Research and development expenses increased 29.4% to $2.0 million, driven by higher material, development and clinical costs. Sales and marketing expenses rose significantly to $975,190 from $128,899 as the company built its commercial team for FemaSeed launch. General and administrative expenses grew 18.8% to $1.6 million due to increased facility and compensation costs.As of June 30, 2024, Femasys had cash and cash equivalents of $13.5 million, which management expects will fund operations into July 2025. However, the company noted substantial doubt about its ability to continue as a going concern beyond 12 months without additional financing. The company is advancing commercialization of its FDA-cleared FemaSeed infertility solution and conducting pivotal trials for its FemBloc permanent birth control candidate.
Femasys Inc. 报告了2024年第二季度的财务结果，营业收入从2023年第二季度的320,514美元下降了30.9%，降至221,484美元，主要由于国际销售的时机因素。销售成本下降33.8%，降至73,125美元，反映了销售减少和制造效率降低。公司的净亏损同比扩大至470万人民币，去年同期为290万人民币。研究和开发费用增加了29.4%，达到200万人民币，主要是由于材料、开发和临床成本上升。销售和市场营销费用显著上升，从128,899美元增加至975,190美元，因为公司在为FemaSeed的推出组建其商业团队。一般和行政费用增长了18.8%，达到160万人民币，原因是设施和薪酬...展开全部
Femasys Inc. 报告了2024年第二季度的财务结果，营业收入从2023年第二季度的320,514美元下降了30.9%，降至221,484美元，主要由于国际销售的时机因素。销售成本下降33.8%，降至73,125美元，反映了销售减少和制造效率降低。公司的净亏损同比扩大至470万人民币，去年同期为290万人民币。研究和开发费用增加了29.4%，达到200万人民币，主要是由于材料、开发和临床成本上升。销售和市场营销费用显著上升，从128,899美元增加至975,190美元，因为公司在为FemaSeed的推出组建其商业团队。一般和行政费用增长了18.8%，达到160万人民币，原因是设施和薪酬成本增加。截至2024年6月30日，Femasys 的现金及现金等价物为1350万人民币，管理层预计这将支持运营到2025年7月。然而，公司指出，若没有额外融资，其在12个月后继续作为一个持续经营实体的能力存在重大怀疑。公司正在推进其获得FDA批准的FemaSeed不孕症解决方案的商业化，并为其FemBloc永久性避孕候选者进行关键试验。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间